Here is a comprehensive analysis of Eli Lilly's federal lobbying and regulatory footprint, drawn entirely from retrieved records.

Eli Lilly & Co. — Federal Lobbying & Regulatory Footprint

1. Lobbying Scale

The corpus contains 300 lobbying filings and 13 LDA Senate filings linked to Eli Lilly & Co. [footprint]. This is a substantial presence. The sampled filings illustrate a multi-firm outside lobbying model operating across multiple quarters:

> Note: These are samples from a 300-filing total. Individual filing bodies were not available in the corpus beyond titles, so specific issue areas and dollar totals across all filings cannot be confirmed from retrieved records. The filing titles confirm a longstanding pattern of simultaneous retention of multiple outside lobbying firms.

2. Lobbying Network (Co-Occurring Entities)

The co-occurrence analysis reveals Lilly's core outside lobbying coalition — firms appearing most frequently alongside the company in LDA disclosures:

• Tarplin, Downs & Young (31 co-filings) — a prominent health-policy and pharma-focused shop
• Venn Strategies (31 co-filings)
• Monument Advocacy (29 co-filings)
• Tiber Creek Health Strategies (25 co-filings)
• The Simmons & Russell Group (24 co-filings)
• Ferox Strategies (21 co-filings)
• Thorn Run Partners (14 co-filings)
• DLA Piper LLP (US) (9 co-filings)

*Assessment: This is an unusually broad stable of retained firms — at least 8 shops appearing with meaningful frequency. This pattern is consistent with a major pharmaceutical company deploying a full-spectrum lobbying strategy across multiple congressional committees and agency touchpoints simultaneously.*

3. FDA Enforcement — Active Warning Letters (September 2025)

This is the most significant current regulatory risk in the corpus. FDA/CDER issued three warning letters on the same date (September 9, 2025) to CEO David A. Ricks, all concerning promotional communications for Lilly's blockbuster GLP-1 drugs.

Letter 1 — Zepbound, MA 824 (okcfox.com video) ^[7]

• Product: ZEPBOUND® (tirzepatide) injection — NDA 217806
• Violation: A sponsored online video (aired July 11, 2025 on Fox25's "Living Oklahoma") featuring Lilly's Dr. Clare Lee and Rhonda Pacheco (Group VP, Diabetes & Obesity) made benefit claims but entirely omitted risk information, including Zepbound's boxed warning for thyroid C-cell tumors, and failed to disclose limitations of use.
• Procedural violation: The video was not submitted to FDA under Form FDA-2253 at time of initial publication, as required by 21 CFR 314.81(b)(3)(i).
• Statutory basis: 21 U.S.C. 352(a), (n); 321(n); 331(a); 21 CFR 202.1(e)(3)(i); (e)(5).

Letter 2 — Zepbound, MA 831 (dayton247now.com video) ^[8]

• Product: ZEPBOUND® (tirzepatide) — NDA 217806
• Violation: A nearly identical sponsored video aired July 9, 2025 on Dayton247 Now, featuring the same two Lilly representatives, with the same pattern: benefit claims for Zepbound (promoting LillyDirect self-pay access) with total omission of risk information and failure to disclose limitations of use.
• Same statutory and regulatory violations as MA 824.

Letter 3 — Zepbound & Mounjaro, MA 974/832 (Oprah ABC Special) ^[9]

• Products: ZEPBOUND® and MOUNJARO® (tirzepatide) — NDAs 217806 & 215866
• Violation: A 42-minute ABC Primetime Oprah Special ("Shame, Blame, and the Weight Loss Revolution," March 18, 2024; also aired on Hulu March 19, 2024) featured Lilly paid consultants (Drs. Butsch and Velazquez) and Lilly's Rhonda Pacheco. FDA found the video:
• Omitted the MEN 2 contraindication from the boxed warning (only MTC history was mentioned);
• Omitted warnings and precautions for severe GI disease, acute kidney injury, hypersensitivity reactions, hypoglycemia, diabetic retinopathy complications, and suicidal behavior/ideation;
• Otherwise created a misleading impression of the drugs' safety profile.
• Aggravating factor: FDA noted prior advisory comments to Lilly on June 13 and June 21, 2022 had already flagged similar risk minimization in Mounjaro draft promotional communications. FDA cited a pattern of non-compliance despite prior notice.

All three letters: Directed Lilly to respond within 15 working days, cease and desist violating promotions, provide corrective communications, and threatened legal action (including seizure and injunction) for inadequate response ^[7][8][9].

4. Federal Register / Regulatory Actions

Strattera (Atomoxetine) — Generic Entry Determination ^[12]

In April 2026, FDA published a Federal Register notice determining that STRATTERA (Atomoxetine Hydrochloride) capsules — held by Eli Lilly under NDA 021411 — were not withdrawn from sale for reasons of safety or effectiveness. Lilly had notified FDA in August 2025 that it was discontinuing the product. This determination means FDA will continue to approve ANDAs referencing Strattera, opening the door to generic competition. *Assessment: This is a commercially significant regulatory event — it confirms Lilly has exited the branded Strattera market and generic manufacturers can now enter freely.*

EUA Revocation — COVID-19 Drug Product ^[11]

A July 2025 Federal Register notice concerns the revocation of an Emergency Use Authorization for a drug product during the COVID-19 pandemic. This record appeared in the corpus in connection with Lilly but the full substance linking it specifically to a Lilly product was not confirmed in the retrieved text; treat as a signal requiring verification.

Sarafem (Fluoxetine) — Drug Approval Withdrawal ^[27]

A March 2024 Federal Register public inspection notice records the withdrawal of approval of Eli Lilly's drug application for Sarafem (Fluoxetine Hydrochloride) Capsules, including the PMDD indication. This is consistent with Lilly's broader portfolio rationalization.

5. SEC Footprint

• 46 SEC filings on record, including 8-K current reports ^[21][22][23]
• 169 SEC filing sections — including 10-K items ^[15][16][17]
• 15 proxy statements, including a 2022 DEF 14A ^[25] and PRE 14A ^[24]
• 34 SC 13D/G filings ^[18][19][20] — reflecting significant institutional ownership/activist investor activity
• 42 insider transactions — including Form 4 filings by JACKSON JAMERE in 2024 and 2025 ^[4][5][6]
• 1 bill linked in the graph (specific bill not retrieved this run)

*The 34 Schedule 13D/G filings are a notable signal — this volume is consistent with Lilly being a heavily held large-cap with active institutional and activist investor monitoring.*

6. Key Regulatory Compliance Risk — Current

The three simultaneous September 9, 2025 FDA warning letters represent the highest-priority active compliance risk in the corpus. Key dimensions:

Coverage & Limitations

Corpora searched: `lobbying_filings` (300 total, 3 sampled), `lda_senate_filings` (13 total, 2 sampled), `sec_filings`, `sec_filing_sections`, `sec_proxy_statements`, `sec_13dg_filings`, `sec_insider_transactions`, `fda_enforcement_letters` (3 total, all retrieved and read), `regulations`, `federal_register_pi_documents`, `executive_orders`, `sec_enforcement_actions`, `cfpb_enforcement_actions`, `crs_reports`.

Gaps & caveats:

• Lobbying issue areas: Individual filing bodies were not available in this run; specific legislative issues lobbied on (e.g., drug pricing, Medicare negotiation, IRA) cannot be cited from retrieved records, though the scale (300 filings, 8+ retained firms) strongly implies broad Hill activity.
• No FARA records found (expected — Lilly is a domestic company).
• No OFAC/LEIE sanctions or exclusions matched.
• Federal contracts/grants: The USAspending corpus backfill is paused; contract/grant data is a floor, not complete.
• SEC enforcement: No SEC or CFPB enforcement actions matched in the title/name search corpus.
• Courts: Thin court-opinion coverage in the corpus; litigation exposure beyond what SEC filings disclose is not confirmed here.
• The `sec_enforcement_actions` and `cfpb_enforcement_actions` corpora returned no hits — this means no title/name match, not a certified-clean litigation record.